Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 20, 2019

Primary Completion Date

July 29, 2020

Study Completion Date

May 6, 2022

Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
DRUG

Metabolic Cofactor Supplementation

Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).

DRUG

Sorbitol

As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).

Trial Locations (1)

34010

Koç University Hospital, Istanbul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Koç University

OTHER

collaborator

Koç University Hospital

UNKNOWN

collaborator

Göteborg University

OTHER

collaborator

Sahlgrenska University Hospital

OTHER

collaborator

KTH Royal Institute of Technology

OTHER

collaborator

University of Helsinki

OTHER

collaborator

Helsinki University Central Hospital

OTHER

collaborator

Monitor CRO

INDUSTRY

lead

ScandiBio Therapeutics AB

INDUSTRY

NCT04330326 - Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease | Biotech Hunter | Biotech Hunter